Maxpro Capital Acquisition Corp - Ordinary Shares - Class A

NASDAQ:JMAC  
10.19
-0.02 (-0.20%)
Products

Apollomics Inc. Receives FDA Orphan Drug Designation For Vebreltinib (Apl-101) For Treatment Of Non-Small Cell Lung Cancer With Met Genomic Tumor Aberrations

Published: 11/15/2022 13:22 GMT
Maxpro Capital Acquisition Corp - Ordinary Shares - Class A (JMAC) - Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (apl-101) for Treatment of Non-small Cell Lung Cancer With Met Genomic Tumor Aberrations.